NCT02293356 - Phase IV Clinical Trial of Nimotuzumab in the Treatment of Nasopharyngeal Carcinoma | Biotech Hunter

Enrollment

2,000

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2017

Conditions

Nasopharyngeal Carcinoma

Interventions

DRUG

Nimotuzumab Injection

patients receive nimotuzumab injection for 200mg/w,intravenous infusion over 60 minutes.Doctor adjust the dosage of nimotuzumab and choose other treatment options according to the actual situation of patients.

Trial Locations (1)

100021

RECRUITING

Cancer Institute & Hospital.Chinese Academy of Medical Sciences, Beijing